Chemotherapy News and Research

Latest Chemotherapy News and Research

GTx achieves enrollment goal for pivotal Phase III clinical studies of enobosarm

GTx, Inc. today announced that it has attained its enrollment goal for both of its pivotal Phase III clinical studies of enobosarm to prevent and treat muscle wasting in non-small cell lung cancer patients.

17 Dec 2012

American Thoracic Society, IASLC and ERS propose new sub-classification of lung adenocarcinomas

The International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS), have proposed a new sub-classification of lung adenocarcinomas.

16 Dec 2012

Two hematology/oncology pharmacists to receive 2012 HOPA Foundation Research Award

The HOPA Foundation Board of Directors is pleased to announce the recipients of the 2012 HOPA Foundation Research Award, Dr. Kamakshi Rao for her project Improving & Defining the Impact & Value of Pharmacists in Stem Cell Transplant, and to Dr. Quan Li, for his project, In Vitro Stability of Erlotinib, Lapatinib and Imatinib in Common Compounding Vehicles.

15 Dec 2012

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

University of Pittsburgh Cancer Institute (UPCI) researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy the cancer cells.

15 Dec 2012

Study describes new, paradoxical characteristics of HER2-negative breast cancer

A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis and treatment of breast cancer.

15 Dec 2012

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.

15 Dec 2012

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

15 Dec 2012

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

14 Dec 2012

High-risk leukemia patients respond to novel drug

A third of adult leukemia patients given the novel drug quizartinib during a phase II study have achieved a composite response of either complete remission, or remission with incomplete platelet recovery or incomplete hematologic recovery, report US researchers.

14 Dec 2012

NCC to expand women's cancer programs in the developing world

The National Cancer Coalition (NCC) is expanding its efforts to fight women's cancers in the developing world.

14 Dec 2012

Biological factors, cell behaviour drive tumour growth contributing to therapy failure and relapse

Cancer scientists led by Dr. John Dick at the Princess Margaret Cancer Centre have found a way to follow single tumour cells and observe their growth over time. By using special immune-deficient mice to propagate human colorectal cancer, they found that genetic mutations, regarded by many as the chief suspect driving cancer growth, are only one piece of the puzzle. The team discovered that biological factors and cell behaviour - not only genes - drive tumour growth, contributing to therapy failure and relapse.

14 Dec 2012

Scientists discover FAIM molecule as potential biomarker for bone marrow cancer

Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow.

14 Dec 2012

Scientists isolate cancer stem cells that lead to growth of Wilms' tumours

Scientists have isolated cancer stem cells that lead to the growth of Wilms' tumours, a type of cancer typically found in the kidneys of young children. The researchers have used these cancer stem cells to test a new therapeutic approach that one day might be used to treat some of the more aggressive types of this disease.

13 Dec 2012

Sirtex unveils new website to learn more about SIR-Spheres microspheres

Sirtex today unveiled a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining increasingly wide acceptance worldwide.

13 Dec 2012

Doctors should use different therapies when treating older and younger patients with CLL

Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

13 Dec 2012

Skin vibrations convey information to the brain much the same way as auditory system

When you walk into a darkened room, your first instinct is to feel around for a light switch. You slide your hand along the wall, feeling the transition from the doorframe to the painted drywall, and then up and down until you find the metal or plastic plate of the switch. During the process you use your sense of touch to develop an image in your mind of the wall's surface and make a better guess for where the switch is.

12 Dec 2012

Review describes current state of lung cancer care

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.

12 Dec 2012

Hospice use driven by finance rather than patient eligibility

Barriers to hospice care in the USA could be more to do with individual hospices' enrollment policies than with patients’ true eligibility, indicate study findings.

12 Dec 2012

African–American rectal cancer patients wait the longest for treatment

African–American rectal cancer patients wait longer for treatment and are less likely to receive adjuvant chemotherapy than their non-African–American counterparts, results show.

12 Dec 2012

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition.

12 Dec 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

GTx achieves enrollment goal for pivotal Phase III clinical studies of enobosarm

American Thoracic Society, IASLC and ERS propose new sub-classification of lung adenocarcinomas

Two hematology/oncology pharmacists to receive 2012 HOPA Foundation Research Award

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

Study describes new, paradoxical characteristics of HER2-negative breast cancer

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

High-risk leukemia patients respond to novel drug

NCC to expand women's cancer programs in the developing world

Biological factors, cell behaviour drive tumour growth contributing to therapy failure and relapse

Scientists discover FAIM molecule as potential biomarker for bone marrow cancer

Scientists isolate cancer stem cells that lead to growth of Wilms' tumours

Sirtex unveils new website to learn more about SIR-Spheres microspheres

Doctors should use different therapies when treating older and younger patients with CLL

Skin vibrations convey information to the brain much the same way as auditory system

Review describes current state of lung cancer care

Hospice use driven by finance rather than patient eligibility

African–American rectal cancer patients wait the longest for treatment

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in